Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues
Executive Summary
Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues